Galectin Therapeutics Inc. (GALT) is Trading Higher on Unusual Volume for February 17

Equities Staff |

Galectin Therapeutics Inc. (GALT) experienced unusually high volume on Feb. 17, as the stock gained 5.45% to a closing price of $1.16. The stock saw 157,627 shares trade hands over the course of the day on 618 trades. Given that the stock’s average daily volume over the last month has been 90,157 shares a day, this represents a pretty substantial spike over the norm.

Galectin Therapeutics Inc. has a P/B ratio of 2.28. The stock has traded between $4.40 and $1.08 over the last 52-weeks, its 50-day SMA is now $1.51, and its 200-day SMA $2.30.

Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Headquartered in Norcross, GA, Galectin Therapeutics Inc. has 7 employees and is currently under the leadership of CEO .

For a complete fundamental analysis analysis of Galectin Therapeutics Inc., check out’s Stock Valuation Analysis report for GALT. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Pressure Biosciences Inc

Pressure BioSciences Inc is a biological life sciences research company. It is engaged in the development and commercialization of a platform technology called pressure cycling technology.

Private Markets

Almond Smart Home Router by Securifi

Securifi sells user friendly touch screen routers that also have support for IoT/home automation.Securifi’s Almond revolutionized wireless router setup with its easy to use Touchscreen Interface in 2012. Now our…

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.